AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 173 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,017,200 | -12.1% | 41,099 | +0.6% | 0.01% | -20.0% |
| Q2 2023 | $1,157,042 | +38.3% | 40,856 | +12.2% | 0.01% | +42.9% |
| Q1 2023 | $836,613 | -20.0% | 36,422 | -2.2% | 0.01% | -22.2% |
| Q4 2022 | $1,045,840 | +23.5% | 37,245 | +24.3% | 0.01% | +12.5% |
| Q3 2022 | $847,000 | +17.5% | 29,955 | -7.8% | 0.01% | +14.3% |
| Q2 2022 | $721,000 | -55.9% | 32,503 | -42.1% | 0.01% | -61.1% |
| Q1 2022 | $1,635,000 | -20.9% | 56,160 | -10.6% | 0.02% | -21.7% |
| Q4 2021 | $2,066,000 | -38.1% | 62,849 | -13.0% | 0.02% | -28.1% |
| Q3 2021 | $3,335,000 | -25.1% | 72,254 | -10.6% | 0.03% | -17.9% |
| Q2 2021 | $4,453,000 | -31.2% | 80,798 | -35.5% | 0.04% | -38.1% |
| Q1 2021 | $6,471,000 | +19.5% | 125,302 | +0.3% | 0.06% | +3.3% |
| Q4 2020 | $5,413,000 | +42.6% | 124,917 | +6.6% | 0.06% | +103.3% |
| Q3 2019 | $3,796,000 | -37.9% | 117,158 | -4.3% | 0.03% | -33.3% |
| Q2 2019 | $6,108,000 | -32.6% | 122,444 | -8.9% | 0.04% | -29.7% |
| Q1 2019 | $9,065,000 | +46.2% | 134,420 | -0.0% | 0.06% | +33.3% |
| Q4 2018 | $6,199,000 | -21.7% | 134,448 | +31.0% | 0.05% | -7.7% |
| Q3 2018 | $7,914,000 | +12.8% | 102,624 | +23.2% | 0.05% | +13.0% |
| Q2 2018 | $7,016,000 | +14.8% | 83,297 | +11.5% | 0.05% | -6.1% |
| Q1 2018 | $6,110,000 | +100.1% | 74,717 | +39.9% | 0.05% | +133.3% |
| Q4 2017 | $3,054,000 | -3.6% | 53,416 | +12.5% | 0.02% | -4.5% |
| Q3 2017 | $3,169,000 | +41.5% | 47,473 | +9.1% | 0.02% | +37.5% |
| Q2 2017 | $2,239,000 | +5.5% | 43,511 | +19.7% | 0.02% | +6.7% |
| Q1 2017 | $2,122,000 | +25.9% | 36,335 | -10.0% | 0.02% | +25.0% |
| Q4 2016 | $1,685,000 | -34.2% | 40,377 | -16.8% | 0.01% | -42.9% |
| Q3 2016 | $2,562,000 | +14.8% | 48,502 | -9.0% | 0.02% | +5.0% |
| Q2 2016 | $2,232,000 | +29.8% | 53,272 | +25.8% | 0.02% | +11.1% |
| Q1 2016 | $1,719,000 | -46.6% | 42,331 | -14.6% | 0.02% | -41.9% |
| Q4 2015 | $3,219,000 | – | 49,586 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |